EUCTR2013-005508-33-CZ进行中（未招募）1 期
Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases - Treosulfan-based versus Busulfan-based conditioning in paediatric patients with non-malignant diseas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non-malignant disease indicated for first myeloablative allogeneic HSCT, including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies and bone marrow failure syndromes.
- •2. First allogeneic HSCT.
- •3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as at least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A, -B, -C, –DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is defined as at least 5/6 matches after two digit typing in HLA-A and -B and four digit typing in DRB1 antigens.
- •4. Age at time of registration from 28 days to less than 18 years of age.
- •5. Lansky (patients <16 years of age) or Karnofsky (patients = 16 years of age) performance score of at least 70%.
- •6. Written informed consent of the parents/legal guardians and patient’s assent/consent according to national regulations.
- •7. Female patients of child-bearing potential or partner of male patients with child-bearing potential must use a highly effective method of contraception (pearl index < 1%) such as complete sexual abstinence, combined oral contraceptive, hormone intrauterine contraceptive device (IUCD), vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients or male partners during the study and at least six months thereafter. For female patients on the study, the vasectomised male partner should be the sole partner for that patient.
- •8. Negative pregnancy test for females of child-bearing potential.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 100
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Second or later HSCT.
- •2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood stem cells (PBSC) or less than 5/6 matched cord donor).
- •3. Preterm newborn infants (<37 weeks gestational age) and term newborn infants aged 0 – 27 days at time of registration.
- •4. Obese paediatric patients with body mass index weight (kg)/[height (m)]² > 30 kg/m².
- •5. Diagnosis of Fanconi anaemia and other chromosomal breakage disorders, radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase 4, Cernunnos- X-ray repair cross-complementing protein 4 (XRCC4) like factor (XLF), Nijmegen Breakage Syndrome (NBS)) and Dyskeratosis Congenita.
- •6. Treatment with cytotoxic drugs within 10 days prior to day 7.
- •7. Impaired liver function indicated by Bilirubin > three times the upper limit of normal (ULN) or aspartate aminotransferase/alanine aminotransferase (AST/GOT, ALT/GPT) > ten times ULN, or clinically significant coagulopathy, or active infectious hepatitis with clinical evidence.
- •8. Impaired renal function indicated by estimated glomerular filtration rate ([GFR], according to the Schwartz formula) < 60 mL/min/1.73m2.
- •9. Impaired cardiac function: severe cardiac insufficiency indicated by left ventricular ejection fraction (LVEF) 35%.
- •10. Requirement for supplementary continuous oxygen.
- •11. Severe active infection requiring deferral of conditioning.
- •12. Human immunodeficiency virus (HIV) positivity.
- •13. Severe concomitant illness, comorbidity or condition that would severely limit life expectancy.
- •14. Known pregnancy, breast feeding.
- •15. Known hypersensitivity to Treosulfan, Busulfan, Fludarabine and/or Thiotepa.
- •16. Participation in another interventional clinical study with an experimental drug, within four weeks prior to patient inclusion.
研究者
相似试验
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesEUCTR2013-005508-33-PLmedac GmbH100
进行中（未招募）
不适用
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesMale and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.MedDRA version: 18.0Level: HLTClassification code 10021606Term: Inborn errors of metabolism NECSystem Organ Class: 100000004850MedDRA version: 18.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870MedDRA version: 18.0Level: HLTClassification code 10018903Term: Haemoglobinopathies congenitalSystem Organ Class: 100000004850EUCTR2013-005508-33-ITmedac GmbH100
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesMale and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.MedDRA version: 20.0Level: HLTClassification code 10021606Term: Inborn errors of metabolism NECSystem Organ Class: 100000004850MedDRA version: 20.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870MedDRA version: 20.0Level: HLTClassification code 10018903Term: Haemoglobinopathies congenitalSystem Organ Class: 100000004850EUCTR2013-005508-33-DEmedac Gesellschaft für klinische Spezialpräparate mbH100
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesEUCTR2013-005508-33-ATmedac Gesellschaft fuer klinische Spezialpräparate mbH100
进行中（未招募）
1 期
Conditioning treatment with treosulfan or busulfan for chemotherapy prior to stem cell transplantation in patients with leukemia.EUCTR2008-002356-18-DEmedac Gesellschaft für klinische Spezialpräparate mbH960